Matinas BioPharma gets NYSE American compliance notice
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain Compliance
June 26, 2026 5:15 PM EDTBEDMINSTER, N.J., June 26, 2026 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (the Company) (NYSE American: MTNB) announced today that on June 24, 2026, it received a notice (the Notice) from the NYSE American LLC (the NYSE American) stating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company Guide (the Company Guide) requiring a company to have stockholders equity of at least $4.0 million if it has reported losses from continuing operations and/or net losses in three of its four most recent... More
